Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies

BackgroundProgrammed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors therapy is now a routine scheme in cancers. However, the effect of preexisting autoantibodies on the safety and efficacy of PD-1/PD-L1 inhibitors in cancer patients is not well understood.MethodsThe pres...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Hui Tang, Ruixuan Geng, Xiuxiu Xu, Yingyi Wang, Jiaxin Zhou, Shulan Zhang, Lin Zhao, Mei Guan, Chunmei Bai
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Immunology
Assuntos:
programmed cell death-1
antinuclear antibody
anti-Ro52 antibody
antithyroid antibody
immune-related adverse events
Acceso en liña:https://www.frontiersin.org/articles/10.3389/fimmu.2022.893179/full
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares